NYHA class5 | |||||
---|---|---|---|---|---|
Heart failure RCTs | N | Ia, % | IIb, % | IIIc, % | IVd, % |
SOLVD 1992 | 4228 | 11–20 | <10 | <10 | <10 |
Munich 1991 | 170 | 11–20 | 11–20 | 11–20 | <10 |
Borghi 2013 | 175 | 11–20 | 11–20 | 11–20 | <10 |
US Carvedilol 1996 | 1094 | >20 | <10 | >20 | <10 |
Liu 2014 | 154 | >20 | <10 | >20 | <10 |
CHARM Added 2003 | 2548 | >20 | <10 | >20 | <10 |
MERIT-HF 1999 | 3991 | >20 | <10 | >20 | <10 |
Zannad 1998 | 254 | >20 | >20 | <10 | <10 |
CELICARD 2000 | 124 | >20 | 11–20 | >20 | <10 |
CHARM Alternative 2003 | 2028 | >20 | 11–20 | >20 | <10 |
SENIORS 2005 | 2128 | >20 | 11–20 | >20 | <10 |
SOLVD 1991 | 2569 | >20 | 11–20 | >20 | <10 |
COMET 2003 | 3029 | >20 | 11–20 | >20 | <10 |
Cicoira 2002 | 106 | e | e | e | e |
CARNEBI 2013 | 183 | >20 | >20 | <10 | >20 |
MAIN CHF II 2014 | 59 | >20 | >20 | <10 | >20 |
Colucci 1996 | 366 | >20 | >20 | <10 | >20 |
Zannad 2011 | 2737 | >20 | >20 | >20 | <10 |
Sturm 2000 | 100 | >20 | >20 | >20 | <10 |
Cohn 2001 | 5010 | >20 | >20 | >20 | <10 |
CIBIS 1994 | 641 | >20 | >20 | >20 | <10 |
CIBIS 1999 | 2647 | >20 | >20 | >20 | <10 |
ELITE II 2000 | 3152 | >20 | 11–20 | >20 | >20 |
Kum 2008 | 100 | >20 | 11–20 | >20 | >20 |
Rieger 1999 | 844 | >20 | >20 | 11–20 | >20 |
BEST 2003 | 226 | >20 | >20 | >20 | >20 |
Dalla-Volta 1999 | 179 | >20 | >20 | >20 | >20 |
AREA-CHF 2009 | 382 | >20 | >20 | >20 | >20 |
Pitt 1999 | 1663 | >20 | >20 | >20 | >20 |
Yodfat 1991 | 84 | e | e | e | e |
a47% of reference population. b36% of reference poulation. c7% of reference population. d10% of reference population. eInsufficient information to calculate deviation. RCT = randomised controlled trial. NYHA = New York Heart Association.